B. Riley Decreases Earnings Estimates for Wave Life Sciences

Wave Life Sciences Ltd. (NASDAQ:WVE) – Equities researchers at B. Riley dropped their Q1 2025 EPS estimates for Wave Life Sciences in a note issued to investors on Wednesday, March 5th. B. Riley analyst M. El-Saadi now expects that the company will post earnings per share of ($0.28) for the quarter, down from their previous forecast of ($0.25). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. B. Riley also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.98) EPS, FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($0.20) EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $1.05 EPS.

Other equities analysts also recently issued reports about the stock. Jefferies Financial Group started coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They issued a “buy” rating and a $26.00 price target on the stock. StockNews.com raised shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday. Mizuho raised their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, Truist Financial raised their price target on shares of Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, November 12th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Wave Life Sciences currently has an average rating of “Moderate Buy” and an average price target of $22.60.

Wave Life Sciences Stock Down 7.7 %

WVE opened at $9.40 on Friday. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -8.47 and a beta of -1.04. Wave Life Sciences has a 52-week low of $4.25 and a 52-week high of $16.74. The firm’s fifty day simple moving average is $11.44 and its two-hundred day simple moving average is $11.24.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million for the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%.

Insider Buying and Selling

In related news, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the sale, the chief executive officer now directly owns 338,351 shares in the company, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 29.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Wave Life Sciences

A number of institutional investors have recently made changes to their positions in WVE. GF Fund Management CO. LTD. acquired a new stake in shares of Wave Life Sciences during the fourth quarter valued at about $40,000. Quarry LP acquired a new stake in shares of Wave Life Sciences during the fourth quarter valued at about $62,000. KBC Group NV acquired a new stake in shares of Wave Life Sciences during the fourth quarter valued at about $67,000. Point72 DIFC Ltd acquired a new stake in shares of Wave Life Sciences during the third quarter valued at about $98,000. Finally, Summit Investment Advisors Inc. increased its position in shares of Wave Life Sciences by 31.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock valued at $119,000 after acquiring an additional 2,308 shares during the last quarter. 89.73% of the stock is currently owned by institutional investors and hedge funds.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.